Predictive and prognostic markers in neuro-oncology

Area of Science:

• Neuro-oncology
• Molecular diagnostics
• Cancer genomics

Background:

• Molecular assays are increasingly used for glioma classification and grading.
• Understanding tumor molecular profiles aids in treatment decisions for gliomas.
• Key molecular markers include 1p/19q loss, EGFR amplification/mutations, and MGMT methylation.

Purpose of the Study:

• To evaluate the application and standardization of molecular assays in glioma management.
• To highlight the need for rigorous testing criteria before clinical adoption.
• To discuss the clinical utility and added value of novel molecular diagnostic tests.

Main Methods:

• Review of current molecular assay applications in glioma diagnostics.
• Discussion of essential validation parameters: inter-/intratest variability, sensitivity, specificity, and predictive values.
• Comparison of different methodologies (e.g., LOH vs. FISH, PCR vs. IHC).

Main Results:

• Molecular markers significantly impact glioma typing, grading, and treatment tailoring.
• Variability in test results across labs and methods poses challenges.
• Robust validation against a gold standard is necessary to assess test accuracy.

Conclusions:

• Standardization and validation are critical for the reliable clinical implementation of molecular glioma assays.
• The added clinical value of new molecular tests must be carefully scrutinized.
• Ensuring test consistency and accuracy is paramount for effective patient care in neuro-oncology.